Doximity's Co-Founder Just Filed a Form 4. Is There Anything in It Worth Worrying About?
Doximity CEO Jeffrey Tangney sold 8,505 shares of Class A Common Stock worth approximately $211,000. This sale was a non-discretionary event to cover tax obligations from vested restricted stock units, representing only a 0.3% reduction in his direct holdings. Tangney still retains a significant 1% ownership interest in the company, amounting to over 2.5 million shares.
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know.
Doximity's CFO, Matthew Sonefeldt, recently filed a Form 4 showing a non-discretionary disposition of 15,311 shares worth approximately $380,000, solely to cover tax withholding obligations from vested restricted stock units. This transaction is not indicative of his outlook on the company, as he retains significant equity. The article also highlights Doximity's business fundamentals, recent financial performance, and Sonefeldt's focus on long-term growth strategies, drawing parallels to LinkedIn's ad business development.
Doximity CAO Siddharth Sitaram sells $44,143 of class A stock By Investing.com
Doximity's Chief Accounting Officer, Siddharth Sitaram, sold 1,770 shares of Class A Common Stock for $44,143 at $24.94 per share. This transaction was part of a Rule 10b5-1 plan to cover tax withholding obligations related to a stock option exercise, where he acquired 5,000 shares. Additionally, 3,882 shares were withheld by Doximity to satisfy tax obligations for restricted stock units.
Doximity CAO Siddharth Sitaram sells $44,143 of class A stock By Investing.com
Siddharth Sitaram, Doximity's Chief Accounting Officer, sold 1,770 shares of Class A Common Stock for $44,143 to cover tax obligations from a stock option exercise. This transaction was part of a pre-arranged trading plan, and despite the stock being down 45% year-to-date, InvestingPro analysis suggests it is undervalued. The company recently reported strong Q1 fiscal 2027 earnings, with increased revenue and a raised full-year outlook, leading to mixed analyst responses regarding its valuation.
Doximity CAO Siddharth Sitaram sells $44,143 of class A stock
Doximity's Chief Accounting Officer, Siddharth Sitaram, sold 1,770 shares of Class A Common Stock for $44,143 to cover tax withholding obligations related to a stock option exercise. This transaction was part of a pre-arranged trading plan. Despite the stock being down 45% year-to-date, InvestingPro analysis suggests it is undervalued, and the company recently reported strong Q1 fiscal 2027 earnings and raised its full-year outlook.
Doximity director Timothy Cabral sells $293,325 in company stock
Doximity director Timothy Cabral sold 7,500 shares of Class A Common Stock for $293,325 on August 7, 2026, as part of a pre-arranged trading plan. On the same day, he exercised options for 7,500 shares of Class B Common Stock, which were then converted to Class A shares. These transactions leave him with 3,221 shares of Class A Common Stock and 326,000 derivative securities.
Doximity director Timothy Cabral sells $293,325 in company stock By Investing.com
Doximity director Timothy Cabral sold 7,500 shares of Class A Common Stock worth $293,325 on August 7, 2026, through a pre-arranged trading plan, while also exercising options for Class B shares. Despite the sale, Doximity is considered undervalued with strong gross profit margins, and the company recently reported first-quarter fiscal 2027 results that exceeded revenue expectations, driven by 7% growth and early success in AI products. However, Wells Fargo downgraded Doximity due to valuation concerns, setting a price target of $18.00.
Doximity director Timothy Cabral sells $293,325 in company stock By Investing.com
Timothy S. Cabral, a director at Doximity, Inc. (NASDAQ:DOCS), sold 7,500 shares of Class A Common Stock for $293,325 on August 7, 2026, executed via a Rule 10b5-1 trading plan. On the same day, he exercised options to acquire 7,500 shares of Class B Common Stock, converting them to Class A. Doximity recently reported Q1 fiscal 2027 revenues exceeding expectations and raised its full-year outlook.
Does Doximity’s Q1 Beat And Higher Guidance Alter The Bull Case For DOCS’ AI Platform?
Doximity (DOCS) reported a fiscal Q1 2027 revenue beat and raised its full-year guidance, with revenue projected to be between US$671 million and US$681 million. Despite the revenue growth, net income fell significantly, highlighting a tension between AI investment, rising costs, and potential regulatory shifts. The article explores how these results influence Doximity's investment narrative, particularly concerning its AI platform and reliance on pharma marketing budgets.
Doximity Inc. Class A (DOCS) Stock Price | Live Quotes & Charts | NYSE
This page provides live stock quotes and charts for Doximity Inc. Class A (DOCS), traded on the NYSE. As of the data provided, DOCS is trading at $27.82, up 34.65% or $7.16. The article also includes general disclaimers about stock trading and the inherent risks involved, specifically noting that most day traders lose money.
Doximity (NYSE:DOCS) Surges on AI Engagement Momentum Despite EPS Miss and Soft Guidance
Doximity (NYSE:DOCS) saw its shares surge by 34% in after-hours trading despite missing EPS estimates and providing soft guidance, indicating that investors are focusing on the company's strong AI engagement momentum and product adoption. The company's Q1 fiscal 2027 revenue was in line with expectations at $156.6 million, but non-GAAP EPS of $0.29 missed the $0.31 consensus, largely due to increased operating expenses tied to AI investments. Investors appear to be prioritizing key usage indicators such as over 30% workflow active prescriber growth and 25% AI Search query growth, alongside the performance of its AI assistant, Doximity Ask.
Doximity Inc. Class A (DOCS) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Doximity Inc. Class A (DOCS) stock, listed on the NYSE. It displays the current stock price, recent percentage change, and offers candlestick line charts for various timeframes. The page also includes information about analyst ratings and earnings for DOCS.
DOCS|Doximity Inc|Price:21.170|Chg%:+0.750
This article provides a comprehensive overview of Doximity Inc (DOCS) stock, including real-time quotes, market trends, key financials, and analyst ratings. It highlights Doximity's strong fundamentals, high growth potential, and a "Buy" rating from analysts with a target price indicating significant upside. The report also details the company's digital platform solutions for medical professionals in the US.
Doximity (DOCS) Is Down 8.0% After Softer Billings Raise Demand And Competition Concerns
Doximity (DOCS) experienced an 8.0% drop in stock price following softer quarterly results, with weak billings indicating slower customer demand and increased competition in its healthcare marketing sector. Despite these challenges, the company's efficient customer acquisition and potential for long-term revenue growth, particularly through its AI tools, remain key focus areas for investors. The article highlights the integration of Doximity's Clinical AI Suite into Aledade's platform as a relevant development, but cautions about the risk of further weakening in pharma marketing demand and healthcare budgets.
Is Doximity (DOCS) Cheap As Its Clinical AI Tool Tops Safety Benchmark?
Doximity (DOCS) is gaining attention after its clinical AI tool, Doximity Ask, achieved a top safety ranking in the NOHARM benchmark. Despite a recent short-term bounce in its share price, the company has experienced significant declines year-to-date and over the past year. Analysts following Doximity suggest it is undervalued, with a fair value of $33.70 compared to its recent close of $22.26, prompting investors to consider if now is the right time to invest.
How Doximity Inc. Class A (DOCS) Affects Rotational Strategy Timing
This article analyzes Doximity Inc. Class A (DOCS) using AI models to determine its effect on rotational strategy timing. It identifies strong near and mid-term sentiment but a weak long-term outlook, with no clear price positioning signal but compelling upside potential due to a lack of resistance above the current price. The analysis provides three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy, along with multi-timeframe signal analysis for support and resistance levels.
How Doximity Inc. Class A (DOCS) Affects Rotational Strategy Timing
This article analyzes Doximity Inc. Class A (DOCS) through an AI-driven quantitative research perspective, providing key findings on sentiment, price positioning, and potential upside. It outlines distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses, based on multi-timeframe signal analysis. The piece also details AI-generated signals and support/resistance levels for various time horizons.
Doximity (NYSE: DOCS) sets 2026 virtual meeting, pay and auditor votes
Doximity, Inc. (NYSE: DOCS) has scheduled its fiscal 2026 annual shareholder meeting for August 27, 2026, as an audio-only virtual event. Shareholders will vote on the election of two Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2027, and an advisory Say-on-Pay resolution for 2026 executive compensation. The board recommends "FOR" all proposals and has provided details on executive compensation, director fees, and corporate governance policies.
Doximity (DOCS) director receives 9,750 RSUs as committee voids part of prior grant
Doximity, Inc. director Benjamin M. Regina was awarded 9,750 restricted stock units (RSUs) as a correction to a previous grant. An earlier grant of 31,064 RSUs was partially voided, with 21,314 RSUs deemed not validly granted. The newly confirmed 9,750 RSUs will vest in four installments through November 15, 2026, resulting in Regina holding a total of 29,589 shares directly after this award.
Equity grant: Doximity (NYSE: DOCS) gives 21,314 RSUs to director
Doximity, Inc. director Benjamin Regina M. was granted 21,314 restricted stock units (RSUs) of Class A common stock on July 13, 2026, under the company's 2021 Stock Option and Incentive Plan. The RSUs have a stated price of $0.0000 per share, with 2,676 units vesting on November 15, 2026, and the remainder vesting in six equal quarterly installments through May 15, 2028, contingent on continued service. Following this grant, Benjamin Regina M. directly holds a total of 50,903 shares of Class A common stock.
Doximity (DOCS) Shifts Into Value Indexes, Is The 32% Undervalued View Right?
Doximity (DOCS) has been reclassified from growth to value and defensive indexes, including the Russell 1000 Value. Despite recent short-term momentum, the stock has seen a significant decline over the past year. Analysts believe Doximity is currently undervalued by 32.2%, with a fair value target of $33.70 against its current $22.86, based on its strong physician user base and potential for monetization.
How Doximity Inc. Class A (DOCS) Affects Rotational Strategy Timing
This article analyzes Doximity Inc. Class A (DOCS) using AI models to provide trading strategies for different risk profiles. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying no resistance levels above the current price. The analysis includes position trading, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss zones.
Is Doximity (DOCS) Rerating Its AI Healthcare Story Amid EPS Pressure And Valuation Discount?
Doximity is facing weaker sentiment due to an expected quarterly EPS decline and only modest revenue growth, despite its focus on AI in healthcare workflows. Analysts are re-evaluating the company's valuation, given its Zacks Rank of #5 (Strong Sell) and a discounted Forward P/E. The core challenge for Doximity is to demonstrate that its AI and workflow products can effectively support earnings and offset rising costs, amidst modest revenue projections for fiscal Q1 2026 and fiscal 2027.
Doximity, Inc. Class A Actuals & Estimates (NYSE:DOCS)
This article provides an overview of Doximity, Inc. (NYSE: DOCS) stock, including its current price, market capitalization, historical performance, and financial estimates. It details analyst forecasts and key financial data such as earnings, revenue, and EBITDA. The article also answers frequently asked questions about Doximity's stock and future outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP is investigating Doximity, Inc. (NYSE: DOCS) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant drop in Doximity's stock price after the company announced its Q4 and fiscal year 2026 financial results, guiding lower revenue and adjusted EBITDA than estimated, citing AI compute costs as a primary concern. Investors affected by the stock price decline are encouraged to contact Pomerantz LLP.
Doximity, Inc. Class A Actuals & Estimates (BX:DOCS)
This article provides financial actuals and estimates for Doximity, Inc. Class A (DOCS) on the BX Swiss exchange. It covers analyst price targets, historical prices, market capitalization, upcoming earnings reports, and past financial performance including earnings, revenue, and net income. The article also confirms that Doximity does not pay dividends and details its employee count and EBITDA figures.
Doximity, Inc. Class A Actuals & Estimates (BMV:DOCS1)
This article provides an overview of Doximity, Inc. Class A (BMV:DOCS1) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, upcoming earnings dates, and financial metrics like revenue, net income, and EBITDA. The content further addresses frequently asked questions about the company's stock, such as volatility and dividend policy.
Doximity (DOCS) President Steven Zatz receives 55,524 restricted stock units
Doximity President Steven L. Zatz was awarded 55,524 restricted stock units (RSUs) of Class A Common Stock on May 15, 2026. These RSUs will vest in equal quarterly installments over 12 months, commencing on August 15, 2026, contingent on his continuous service. Following this grant, Zatz directly holds 56,346 shares of Class A Common Stock.
Doximity (DOCS) CFO discloses 501,549 shares, including 499,722 RSUs, on Form 3
Doximity, Inc.'s Chief Financial Officer, Matthew Sonefeldt, filed an initial ownership report (Form 3) disclosing 501,549 shares of Class A Common Stock. This figure includes 499,722 restricted stock units (RSUs) granted on May 15, 2026, which will vest in equal quarterly installments over 36 months, starting August 15, 2026, contingent on continued service. This filing does not represent a buy or sell transaction but rather an initial disclosure of beneficial ownership.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP has initiated an investigation into potential securities fraud and unlawful business practices by Doximity, Inc. (NYSE: DOCS) and its officers/directors. This investigation follows Doximity's announcement of fourth-quarter and fiscal year 2026 financial results, where the company's revenue and adjusted EBITDA guidance fell below estimates, citing AI computing costs as a contributing factor. The news led to a 23% drop in Doximity's stock price on May 14, 2026.
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Doximity, Inc. (NYSE: DOCS) for potential securities law violations. This comes after Doximity missed full-year revenue consensus estimates and its CEO warned that increased AI investment would impact near-term margins, leading to a 23% stock drop. The firm is encouraging affected shareholders to join the fraud investigation.
Doximity interim PAO Sitaram Siddharth sells $49,882 in shares
Doximity's interim PAO, Sitaram Siddharth, sold 2,444 shares of Class A Common Stock for $49,882, primarily to cover tax obligations related to exercising stock options. Earlier the same day, Siddharth acquired 5,000 Class A shares through the conversion of Class B shares. This comes as Doximity faces analyst downgrades and reduced price targets after forecasting lower-than-expected fiscal 2027 revenue.
Doximity interim PAO Sitaram Siddharth sells $49,882 in shares
Doximity Interim PAO Sitaram Siddharth sold $49,882 worth of Class A Common Stock, a transaction identified as a "sell-to-cover" to satisfy tax obligations. This sale was automatically executed under a Rule 10b5-1 trading plan. Siddharth also acquired 5,000 Class A shares through a conversion from Class B shares, and now directly holds 90,706 Class A shares.
[Form 4] Doximity, Inc. Insider Trading Activity
Doximity, Inc.'s interim PAO, Sitaram Siddharth, reported selling 2,444 shares of Class A Common Stock at $20.41 per share, primarily to cover tax withholding obligations from a stock option exercise. He also exercised and converted derivative securities for a total of 15,000 shares, including 5,000 Class B shares convertible to Class A. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan and are considered routine compensation mechanics rather than a discretionary reduction in his holdings.
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Doximity, Inc. (NYSE: DOCS) on behalf of investors for potential securities law violations. This investigation follows Doximity's Q4 and full-year 2026 financial results, where the company missed revenue estimates and warned that increased AI investment would impact near-term margins, leading to a 23% stock drop. Shareholders who experienced losses are encouraged to contact the firm for a free consultation.
Doximity interim PAO Sitaram Siddharth sells $49,882 in shares By Investing.com
Doximity Interim PAO Sitaram Siddharth sold $49,882 worth of Class A Common Stock to cover tax obligations related to a stock option exercise, following an earlier conversion of Class B to Class A shares. The stock is currently trading near its 52-week low and is considered undervalued by InvestingPro analysis, despite recent mixed analyst ratings and updated fiscal 2027 revenue guidance.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP has launched an investigation into Doximity, Inc. (NYSE: DOCS) on behalf of investors, following a significant drop in Doximity's stock price. The investigation concerns potential securities fraud or unlawful business practices, particularly after Doximity's May 13, 2026, financial results announcement. The company's guidance for full-year revenue and adjusted EBITDA fell below estimates, with management citing increased AI compute costs impacting margins, leading to a 23% stock price decline.
Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
Doximity (DOCS) reported a mixed fiscal Q4 2026, with adjusted EPS missing estimates by 7.1% while revenues surpassed expectations by 1.2%. The company's adjusted gross and operating margins contracted, leading to a 19.3% drop in stock price after hours. Despite the earnings miss, Doximity saw growth in platform engagement and AI adoption, with strong net revenue retention and expansion of its clinical AI suite.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP is investigating Doximity, Inc. (NYSE: DOCS) on behalf of investors regarding potential securities fraud and unlawful business practices. This investigation follows Doximity's announcement of Q4 and fiscal year 2026 financial results, which included lower-than-estimated revenue guidance and concerns about AI compute costs impacting margins. Consequently, Doximity's stock price fell significantly, prompting the class action investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP is investigating potential securities fraud claims against Doximity, Inc. (NYSE: DOCS) on behalf of its investors. This investigation follows a significant drop in Doximity's stock price after the company announced lower-than-estimated full-year revenue guidance and warned about AI compute costs impacting near-term margins. Investors are encouraged to contact Pomerantz LLP to learn more about joining a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
Pomerantz LLP is investigating Doximity, Inc. (NYSE: DOCS) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Doximity's announcement of fourth-quarter and fiscal year 2026 financial results, which included lower-than-estimated revenue guidance and adjusted EBITDA, primarily due to increased AI compute costs. As a result, Doximity's stock price dropped by 23% on May 14, 2026.
1,246 Doximity (DOCS) shares withheld to cover RSU taxes for interim PFO
Doximity's interim PFO and PAO, Siddharth Sitaram, had 1,246 Class A Common Stock shares withheld by the company to satisfy tax obligations related to vesting Restricted Stock Units (RSUs). This was a mandatory tax-withholding disposition, not a discretionary trade, at a price of $18.01 per share. Following this transaction, Sitaram directly owns 88,150 shares of Doximity.
Doximity (NYSE: DOCS) CEO granted PSUs while shares withheld for tax
Doximity, Inc.'s CEO, Jeffrey Tangney, was granted 322,614 shares of Class A Common Stock as performance-based restricted stock units (PSUs). Simultaneously, 14,964 shares were withheld at $18.01 each to cover tax obligations on previously vested units, which was a mandated non-discretionary action. After these transactions, Tangney directly holds 2,555,424 Class A shares, with future PSU vesting scheduled for May 2026 and May 2028.
Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed
Doximity (DOCS) recently reported Q4 and full-year fiscal 2026 results, showing revenue growth but declining net income due to profitability pressure. The company's stock fell 27.0% following a softer fiscal 2027 outlook and increased AI-related spending, which sharpens concerns about its investment narrative despite a new AI integration with Aledade. Analysts are now re-evaluating their forecasts, with some already cautious about slower revenue growth and shrinking margins.
Doximity (DOCS) Margin Compression Challenges Bullish AI Growth Narratives After FY 2026 Results
Doximity (DOCS) has reported its FY 2026 results, showing Q4 revenue of US$145.4 million and basic EPS of US$0.10, with trailing net profit margins falling to 30.4% from 39.1% a year prior. This margin compression and slower projected revenue growth of 5.2% per year challenge bullish AI-driven growth narratives, despite the stock trading at a P/E of 17x and significantly below its DCF fair value. Analysts forecast modest earnings growth of 2.2% annually, leading to tension between optimistic long-term AI potential and current financial realities.
Doximity (DOCS) founders report combined stakes equal to 77% voting power
Doximity, Inc. founders Jeffrey Tangney and Claudia Schweikert, along with related trusts, have filed an amendment to their Schedule 13G/A, detailing their beneficial ownership stakes in the company. The filing indicates that Tangney and Schweikert each beneficially own 55,459,800 shares, representing 29.9% of Class A on a conversion basis. Due to Doximity's dual-class share structure where Class B shares carry ten votes each, their combined holdings account for 77.0% of the aggregate voting power.
Doximity Ties Clinical AI To Aledade And New Pharma Search Revenue
Doximity (NYSE:DOCS) has partnered with Aledade to integrate its HIPAA-compliant Clinical AI Suite into Aledade’s EHR overlay platform, targeting value-based primary care. This integration aims to streamline documentation and provide clinical insights. Additionally, Doximity is monetizing its AI-driven search product for pharmaceutical marketers, opening a new revenue channel.
Stock Market Today: S&P 500, Dow Jones Futures Gain As Trump Clears NVDA's H200 Sales To China—Cisco Systems, Doximity, Grocery Outlet In Focus
U.S. stock futures rose on Thursday, with the S&P 500 and Dow Jones Futures gaining ground amidst President Trump's visit to China and the clearance of Nvidia's H200 AI chip sales to some Chinese firms. Cisco Systems, Doximity, and Grocery Outlet were among the stocks in focus due to significant price movements following earnings reports and guidance updates. Analysts from BlackRock maintained a pro-risk stance on U.S. equities, even as the market navigates ongoing inflationary pressures and rising long-term yields.
These Analysts Slash Their Forecasts On Doximity After Q4 Results
Doximity (NYSE: DOCS) reported mixed fourth-quarter results, beating revenue estimates but missing on adjusted earnings, and provided weak first-quarter and fiscal 2027 sales guidance. Following this, several analysts downgraded the stock or lowered their price targets, despite the company's report of increased user engagement. Doximity's shares dropped significantly in pre-market trading after the announcement.
Doximity interim PFO Siddharth sells $59,502 of class A stock By Investing.com
Sitaram Siddharth, Interim PFO and PAO at Doximity (NYSE:DOCS), sold 2,309 shares of Class A Common Stock for $59,502 on May 11, 2026, as part of a Rule 10b5-1 trading plan and for tax obligations. Simultaneously, he acquired 5,000 Class A shares by converting Class B shares from a stock option exercise. Despite recent stock weakness, InvestingPro analysis suggests Doximity is undervalued with strong financial health, and the company recently reported mixed Q4 earnings but provided strong fiscal 2027 revenue guidance.
